ZYME Jul 2024 7.500 call
| Previous close | 2.7500 |
| Open | 2.7400 |
| Bid | 1.4500 |
| Ask | 2.2500 |
| Strike | 7.50 |
| Expiry date | 2024-07-19 |
| Day's range | 2.7400 - 2.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 27 |
Simply Wall St.Zymeworks (NASDAQ:ZYME) investors are sitting on a loss of 75% if they invested three years ago
It's not possible to invest over long periods without making some bad investments. But really bad investments should be...
GlobeNewswireZymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164 million based on additional milestones plus royalties on product salesA Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) ha
- GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on June 5-6 and a fireside chat
